YZYoufu Zhu

Youfu Zhu

*This is an algorithmically generated author record based on publicly available information.

Youfu Zhu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TMEM100 Regulates Neuropathic Pain by Reducing the Expression of Inflammatory Factors

    by Huifei Cui, Zhaoyang Guo, Zhu Guo, Zuoran Fan, Nana Shen, Xiaoying Qi, Yuanye Ma, Youfu Zhu, Xiaolin Wu, Bohua Chen, et al.

    There is no effective treatment for peripheral nerve injury-induced chronic neuropathic pain (NP), which profoundly impacts the quality of life of those affected. Transmembraneprotein100 (TMEM100) is considered to be a pain regulatory protein and is expressed in the dorsal root ganglion (DRG) of rats. However, the mechanism of pain regulation and the expression of TMEM100 following various peripheral nerve injuries are unclear. In this study, we constructed two pain models of peripheral nerve injury: tibial nerve injury (TNI) and chronic constriction injury (CCI). This study found that the Paw Withdrawal Mechanical Threshold (PWMT) and Paw Withdraw Thermal Latency (PWTL) of the rats in the two pain models decreased significantly, and the expression of TMEM100 in the DRG of two groups also decreased significantly. Furthermore, the decrease in the CCI group was more obvious than in the TNI group. There was no significant statistical significance ( ). We constructed an adeno-associated virus 6 (AAV6) vector expressing recombinant fluorescent TMEM100 protein and injected it into the sciatic nerve (SN) of two pain models: CCI and TNI. PWMT and PWTL were significantly increased in the two groups, along with the expression of TMEM100 in the spinal cord and DRG. It also significantly inhibited the activation of microglia, astrocytes, and several inflammatory mediators (TNF- α, IL-1 β, and IL-6). In summary, the results of this study suggested that TMEM100 might be a promising molecular strategy for the treatment of NP, and its anti-inflammatory effects might play an important role in pain relief.


  • Open Access

    Anterior Cervical Discectomy and Fusion Using Zero-P System for Treatment of Cervical Spondylosis: A Meta-Analysis

    by Zhaoyang Guo, Xiaolin Wu, Shuai Yang, Chang Liu, Youfu Zhu, Nana Shen, Zhu Guo, Weiliang Su, Yan Wang, Bohua Chen, et al.

    Objective. The current study aimed to explore the efficacy of Zero profile intervertebral fusion system (Zero-P) and traditional anterior plate cage system (PC) in the treatment of cervical spondylotic myelopathy (CSM). Further, the present study evaluated effects of the treatments on medical security, height of intervertebral disc, adjacent-level ossification development (ALOD), and adjacent segmentation disease (ASD) through a systematic retrospective analysis. Methods. Studies on Zero-P system and traditional anterior plate cage system for ACDF in the treatment of CSM were searched in PubMed, Web of Science, Ovid, Embase, and Cochrane Library databases. Two independent researchers screened articles, extracted data, and evaluated the quality of the articles based on the inclusion and exclusion criteria of the current study. RevMan5.3 software was used for meta-analysis following the guidelines of Cochrane collaboration network. Cervical curvature, interbody fusion rate, preoperative and postoperative disc height index (DHI), fusion cage sinking rate, postoperative dysphagia, ASD, ALOD, and loosening of screw were compared between the two groups. Results. A total of 17 literatures were included in the present study, including 6 randomized controlled trials and 11 observational studies. The studies comprised a total of 1204 patients with CSM, including 605 patients in the Zero-P system group (Zero-P group) and 599 patients in the traditional animal plate cage group (PC group). Results of this meta-analysis showed that postoperative dysphagia [OR = 0.40, CI (0.28, 95% 0.58), < 0.00001], ALOD [OR = 0.09, CI (0.02, 95% 0.39), = 0.001], ASD [OR = 0.42, CI (0.20, 95% 0.86), = 0.02], and screw loosening [OR = 0.20, CI (0.08, 95% 0.52), = 0.0009] of the Zero-P group were significantly lower compared with the PC group. On the other hand, preoperative cervical curvature [WMD = −0.23, CI (−1.38, 95% 0.92), = 0.69], postoperative cervical curvature [WMD = −0.38, CI (−1.77, 95% 1.01), = 0.59], cage sinking rate [OR = 1.41, CI [0.52, 95% 3.82], = 0.50], intervertebral fusion rate [OR = 0.76, CI (0.27, 95% 2.48), = 0.38], preoperative DHI [WMD = −0.04, CI (−0.14, 95% 0.22), = 0.65], and postoperative DHI [WMD = 0.06, CI (−0.22, 95% 0.34), = 0.675] were not significantly different between the two groups. Conclusion. It was evident that the Zero-P system used in ACDF is superior compared with the traditional anterior plate cage system in postoperative dysphagia, avoiding ALOD, ASD, and screw loosening.


  • Open Access

    THAP9‐AS1 Promotes Tumorigenesis and Reduces ROS Generation through the JAK2/STAT3 Signaling Pathway by Increasing SOCS3 Promoter Methylation in Osteosarcoma

    by Shuai Yang, Bing Wang, Chang Liu, Qizun Wang, Ronghuan Wang, Weiliang Su, Youfu Zhu, Maohua Li, Zhaoyang Guo, Xiaolin Wu, et al.

    Increasing studies have demonstrated that dysfunction of long noncoding RNAs (lncRNAs) plays critical roles in the development of human cancers. THAP9‐AS1 has been reported to be dysregulated and associated with tumor progression in some cancers. However, the function and mechanism of THAP9‐AS1 in osteosarcoma (OS) remain unclear. In the present study, we found that the expression of THAP9‐AS1 was significantly upregulated in OS tissues and associated with the advanced stage of tumors and poor prognosis of patients. Blast comparison results showed that the SOCS3 promoter region and THAP9‐AS1 had base complementary pairing binding sites. The interactions between THAP9‐AS1, DNA methyltransferases (DNMTs), and SOCS3 were assessed by RIP and ChIP assays. The results of methylation‐specific PCR (MSP) and bisulfite sequencing PCR (BSP) validated that THAP9‐AS1 enhanced the methylation level of the SOCS3 promoter. The mRNA levels of SOCS3 in OS cells could be reversed by the demethylation agent 5‐aza‐2 ′‐deoxycytidine. The mRNA expression of SOCS3 was downregulated in OS tissues and negatively correlated with THAP9‐AS1 expression in tumors. Moreover, the western blot and immunofluorescence (IF) assay data showed that THAP9‐AS1 activated the JAK2/STAT3 signaling pathway by upregulating p‐JAK2 and p‐STAT3 and the nuclear translocation of p‐STAT3. Functionally, ectopic expression of THAP9‐AS1 promoted cell proliferation, migration, and invasion and inhibited apoptosis, and this phenomenon could be reversed by SOCS3. Introduction of the JAK/STAT inhibitor AG490 partially abolished the stimulative effect of THAP9‐AS1 on cellular processes. In addition, THAP9‐AS1 decreased oxidative stress by reducing reactive oxygen species (ROS) and enhancing the mitochondrial membrane potential of OS cells via the SOCS3/JAK2/STAT3 pathway. Stable overexpression of THAP9‐AS1 contributed to tumor growth and metastasis in vivo. In total, our findings suggested that upregulation of THAP9‐AS1 might recruit DNMTs to epigenetically inhibit SOCS3, thereby activating the JAK2/STAT3 signaling pathway and oncogenesis of OS. These results provide novel insights for the understanding of OS progression.


  • Open Access

    Glycine‐Serine‐Threonine Metabolic Axis Delays Intervertebral Disc Degeneration through Antioxidant Effects: An Imaging and Metabonomics Study

    by Xiaolin Wu, Chang Liu, Shuai Yang, Nana Shen, Yan Wang, Youfu Zhu, Zhaoyang Guo, Shang-You Yang, Dongming Xing, Houxi Li, et al.

    Although intervertebral disc degeneration (IDD) can be described as different stages of change through biological methods, this long and complex process cannot be defined in stages by single or simple combination of biological techniques. Under the background of the development of nuclear magnetic resonance (NMR) technology and the emerging metabonomics, we based on animal models and expanded to the study of clinical human degeneration models. The characteristics of different stages of IDD were analyzed by omics. Omics imaging combined with histology, cytology, and proteomics was used for screening of the intervertebral disc (IVD) of research subjects. Furthermore, mass spectrometry nontargeted metabolomics was used to explore profile of metabolites at different stages of the IDD process, to determine differential metabolic pathways and metabolites. NMR spectroscopy was used to qualitatively and quantitatively identify markers of degeneration. NMR was combined with mass spectrometry metabolomics to explore metabolic pathways. Metabolic pathways were determined through protein molecular biology and histocytology of the different groups. Distinguishing advantages of magnetic resonance spectroscopy (MRS) for analysis of metabolites and effective reflection of structural integrity and water molecule metabolism through diffusion tensor imaging (DTI) were further used to verify the macrometabolism profile during degeneration. A corresponding model of in vitro metabolomics and in vivo omics imaging was established. The findings of this study show that a series of metabolic pathways associated with the glycine‐serine‐threonine (Gly‐Ser‐Thr) metabolic axis affects carbohydrate patterns and energy utilization efficiency and ultimately delays disc degeneration through antioxidant effects.